Compare Gilead Sciences, Inc. (GILD) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Seagate Technology Holdings PLC — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Seagate Technology Holdings PLC trades at $779.8 (market cap $176.19B). The key difference: Gilead Sciences, Inc. and Seagate Technology Holdings PLC are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Seagate Technology Holdings PLC for 41 Days on average.
| GILD | STX | |
|---|---|---|
Market Cap | $182.40B | $176.19B |
Volume | 4,469,821 | 5,061,875 |
Sector | Health | Technology |
52-Week High | $155.80 | $1.09K |
52-Week Low | $116.74 | $211.63 |
Typical Hold Time | 111 Days | 41 Days |
Enterprise Value | $205.46B | $178.34B |
Dividend Yield | 2.23% | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Seagate Technology (STX) trades at $807.34, up 0.21% with bearish technical signals despite strong fundamental performance. The company reported Q2 2026 EPS of $5.71, beating estimates by 12%, and maintains robust profitability with 26.11% net margins. Recent news highlights competitive pressures as Toshiba plans to expand AI storage production, potentially challenging Seagate's pricing power in the high-capacity drive market.
While analyst consensus remains bullish with a $1,130 price target, near-term risks include increased competition and volatile cash flows. The stock's elevated valuation ratios (P/E 58.1, P/S 15.16) require sustained earnings growth justification, particularly as technical indicators signal caution with resistance at $816.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
